Outcome Measures
What is the Role of the Outcome Measures Working Group?
Our Outcome Measures Working Group is responsible for selecting the primary, secondary, interim and exploratory outcome measures for the trial. The measures chosen must be clinically relevant, meaningful to patients, meet regulatory requirements and be accessible for use.
Meet the Chair
Professor Anette Schrag
Professor Schrag is Professor of Clinical Neurosciences and Consultant Neurologist at University College London.
Prof. Schrag’s research has focused on movement disorders, including biomarker studies to improve early diagnosis, clinical trials to reduce symptoms and progression, and the developing tools for the measurement of clinical features. She has pioneered a patient-centred approach in assessing outcomes of clinical trials in Parkinson’s disease and the inclusion and development of patient-oriented outcome measures in other movement disorders.
Professor Schrag leads our Outcome Measures Working Group in determining the best primary, secondary and exploratory measures for use in the EJS ACT-PD trial.
Members of this working group
| Rimona Weil, Deputy Chair | University College London |
| Daniel van Wamelen, Early Career Researcher | Kings College London |
| Caroline Williams Gray | University of Cambridge |
| Michele Hu | University of Oxford |
| Lynn Rochester | Newcastle University |
| Paola Piccini | Imperial College London |
| Henrik Zetterberg | Univerity College London |
| Alastair Noyce | Queen Mary University of London |
| Caroline S. Clarke | University College London |
| Michael Lawton | University of Bristol |
| Matthew Burnell | Medical Research Council Clinical Trials Unit, London |
| Ashwani Jha | Univerity College London |
| Brook Huxford | Queen Mary University of London |
| Carroll Siu | PPI member, Kent |
| Michèle Bartlett | PPI member, Surrey |